双路化疗免疫序贯治疗非小细胞肺癌胸腔积液

Systemic chemotherapy combined with intrathoracic sequent immunotherapy for patients with malignant pleural effusion due to non-small cell lung cancer (NSCLC)

目的综合观察双路化疗免疫序贯疗法治疗非小细胞肺癌胸腔积液的临床疗效及相关免疫指标的变化。方法42例肺癌胸腔积液患者随机分入观察组和治疗组,各21例。两组均予以GP方案化疗2个周期,在化疗第15天开始尽量排净胸水,观察组予以胸腔内注射IL-2,每3d1次,连续4次;对照组仅间断放胸水以缓解症状,检测两组治疗前和治疗后1个月的胸水中T淋巴细胞数量;治疗1个月后观察胸水缓解率。结果观察组临床缓解有效率达85.7%,与对照组57.1%比较,差异有显著性(P<0.05)。观察组治疗后胸水中T淋巴细胞的数量均明显高于对照组,差异有显著性(P<0.001)。结论双路化疗免疫序贯疗法在增加免疫细胞数量的同时临床疗效明显。

[Objective] To evaluate the effectiveness and the changes of relative immune parameters in the treatment of malignant pleural effusion, caused by NSCLC, through Systemic chemotherapy combined with intrathoracic sequent immunotherapy. [Methods] 42 patients were divided into two groups： observed group （21 cases） and the control group （21 cases）. Systemic chemotherapy （GP scheme, two period） were performed and the pleural effusion was drained thoroughly. From the 15th day IL-2 were injected into pleural cavity for the observed group once every 3 days 4 for times continually. At the same time for the control group, the pleural effusion was drained at intervals only. The detection of the number of T lymphocytes in the pleural effusion for all patients was done before and after therapy one month later. The effectiveness was evaluated in the both groups one month later. [Results] The ratio of resume of malignant pleurisy in observed group was 85.7% 57.1% and in control, the difference was obvious （P 〈0.05）. It was obvious （P 〈0.001） that the number of T lymphocytes increased more in observed group than in the control. [Conclusion] The number of immunological cells has increased in systemic chemotherapy combined with intrathoracic sequent immunotherapy, as well as the curative effect.